Ignite Creation Date:
2024-05-06 @ 4:04 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02443324
Status:
COMPLETED
Last Update Posted:
2022-08-18
First Post:
2015-05-11
Brief Title:
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma NSCLC Transitional Cell Carcinoma of the Urothelium or Biliary Tract Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-07-29
Start Date Type:
ACTUAL
Primary Completion Date:
2018-08-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-12
Completion Date Type:
ACTUAL
First Submit Date:
2015-05-11
First Submit QC Date:
May 11 2015
Study First Post Date:
2015-05-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-19
Last Update Post Date:
2022-08-18
Last Update Post Date Type:
ACTUAL